|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NARFL |
Gene summary for NARFL |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NARFL | Gene ID | 64428 |
| Gene name | cytosolic iron-sulfur assembly component 3 | |
| Gene Alias | HPRN | |
| Cytomap | 16p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0001666 | UniProtAcc | Q9H6Q4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 64428 | NARFL | P1T-E | Human | Esophagus | ESCC | 3.53e-14 | 5.71e-01 | 0.0875 |
| 64428 | NARFL | P2T-E | Human | Esophagus | ESCC | 8.70e-49 | 7.68e-01 | 0.1177 |
| 64428 | NARFL | P4T-E | Human | Esophagus | ESCC | 3.75e-20 | 5.11e-01 | 0.1323 |
| 64428 | NARFL | P5T-E | Human | Esophagus | ESCC | 9.67e-18 | 2.74e-01 | 0.1327 |
| 64428 | NARFL | P8T-E | Human | Esophagus | ESCC | 1.77e-24 | 3.65e-01 | 0.0889 |
| 64428 | NARFL | P9T-E | Human | Esophagus | ESCC | 2.41e-05 | 1.67e-01 | 0.1131 |
| 64428 | NARFL | P10T-E | Human | Esophagus | ESCC | 8.56e-12 | 1.58e-01 | 0.116 |
| 64428 | NARFL | P11T-E | Human | Esophagus | ESCC | 6.58e-08 | 4.49e-01 | 0.1426 |
| 64428 | NARFL | P12T-E | Human | Esophagus | ESCC | 7.27e-29 | 4.78e-01 | 0.1122 |
| 64428 | NARFL | P15T-E | Human | Esophagus | ESCC | 1.71e-21 | 3.82e-01 | 0.1149 |
| 64428 | NARFL | P16T-E | Human | Esophagus | ESCC | 3.60e-13 | 2.29e-01 | 0.1153 |
| 64428 | NARFL | P17T-E | Human | Esophagus | ESCC | 2.78e-09 | 3.30e-01 | 0.1278 |
| 64428 | NARFL | P19T-E | Human | Esophagus | ESCC | 5.81e-10 | 4.90e-01 | 0.1662 |
| 64428 | NARFL | P20T-E | Human | Esophagus | ESCC | 8.18e-19 | 4.19e-01 | 0.1124 |
| 64428 | NARFL | P21T-E | Human | Esophagus | ESCC | 2.01e-19 | 3.19e-01 | 0.1617 |
| 64428 | NARFL | P22T-E | Human | Esophagus | ESCC | 2.06e-18 | 2.96e-01 | 0.1236 |
| 64428 | NARFL | P23T-E | Human | Esophagus | ESCC | 8.32e-25 | 5.20e-01 | 0.108 |
| 64428 | NARFL | P24T-E | Human | Esophagus | ESCC | 3.89e-12 | 2.50e-01 | 0.1287 |
| 64428 | NARFL | P26T-E | Human | Esophagus | ESCC | 2.20e-17 | 3.27e-01 | 0.1276 |
| 64428 | NARFL | P27T-E | Human | Esophagus | ESCC | 3.63e-23 | 4.82e-01 | 0.1055 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NARFL | SNV | Missense_Mutation | novel | c.410N>T | p.Arg137Met | p.R137M | Q9H6Q4 | protein_coding | deleterious(0.01) | possibly_damaging(0.717) | TCGA-AR-A250-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| NARFL | SNV | Missense_Mutation | novel | c.839T>G | p.Leu280Trp | p.L280W | Q9H6Q4 | protein_coding | deleterious(0) | possibly_damaging(0.469) | TCGA-BH-A0B1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin | SD |
| NARFL | SNV | Missense_Mutation | c.295N>C | p.Asp99His | p.D99H | Q9H6Q4 | protein_coding | tolerated(0.12) | benign(0.015) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR | |
| NARFL | insertion | Frame_Shift_Ins | novel | c.837_838insGGTCCTCCCACAGAGGTGGGCTGGGTGGAGGGCAGCC | p.Leu280GlyfsTer71 | p.L280Gfs*71 | Q9H6Q4 | protein_coding | TCGA-BH-A0B1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin | SD | ||
| NARFL | deletion | Frame_Shift_Del | novel | c.1000delA | p.Ile334SerfsTer11 | p.I334Sfs*11 | Q9H6Q4 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| NARFL | SNV | Missense_Mutation | c.267N>C | p.Gln89His | p.Q89H | Q9H6Q4 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-C5-A1MQ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| NARFL | SNV | Missense_Mutation | c.146N>T | p.Tyr49Phe | p.Y49F | Q9H6Q4 | protein_coding | deleterious(0.04) | benign(0.274) | TCGA-EA-A411-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| NARFL | SNV | Missense_Mutation | c.1288N>A | p.Glu430Lys | p.E430K | Q9H6Q4 | protein_coding | tolerated(0.51) | benign(0.012) | TCGA-FU-A2QG-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| NARFL | SNV | Missense_Mutation | rs376966046 | c.208N>A | p.Asp70Asn | p.D70N | Q9H6Q4 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-IR-A3LI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| NARFL | insertion | Frame_Shift_Ins | novel | c.73_74insC | p.Ile25ThrfsTer20 | p.I25Tfs*20 | Q9H6Q4 | protein_coding | TCGA-DS-A1OC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | gemcitabine | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |